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Background:  The  diagnosis  of  Ebola  virus disease  relies  on  the  detection  of  viral  RNA  in blood  by  real-
time  reverse-transcription  PCR.  While  several  of  these  assays  were  developed  during  the unprecedented
2013–2015  Ebola  virus  disease  outbreak  in  West  Africa,  few  were  applied  in  the  ﬁeld.
Objectives:  To  compare  technical  performances  and  practical  aspects  of 11  Ebola  virus  real-time  reverse-
transcription  PCR  procedures.
Study  design:  We  selected  the  most  promising  assays  using  serial  dilutions  of  culture-derived  Ebola  virus
RNA and  determined  their analytical  sensitivity  and  potential  range  of  quantiﬁcation  using  quantiﬁed
in  vitro  transcribed  RNA;  viral  load  values  in  the  serum  of  an  Ebola  virus disease  patient  obtained  with
these  assays  were  reported.  Finally,  ease  of use  and  turnaround  times  of these  kits  were  evaluated.
Results:  Commercial  assays  were  at least  as  sensitive  as in-house  tests.  Five  of the former  (Altona,  Roche,
Fast-track  Diagnostics,  and  Life Technologies)  were  selected  for further  evaluation.  Despite  differences
in  analytical  sensitivity  and  limits  of  quantiﬁcation,  all  of them  were  suitable  for  Ebola  virus  diagnosis
and  viral  load  estimation.  The  Lifetech  Lyophilized  Ebola  Virus  (Zaire  2014)  assay  (Life  Technologies)
appeared  particularly  promising,  displaying  the  highest  analytical  sensitivity  and  shortest  turnaround
time,  in  addition  to  requiring  no reagent  freezing.
Conclusions:  Commercial  kits  were  at least  as sensitive  as  in-house  tests  and  potentially  easier to  use in
the  ﬁeld  than  the latter. This  qualitative  comparison  of real-time  reverse  transcription  PCR assays  may
serve  as  a basis  for  the design  of  future  Ebola  virus  disease  diagnostics.
© 2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Background
As of September, 2015, more than 28,000 cases and over
1,000 deaths have occurred during the West African epidemic
f Ebola virus disease (EVD) (http://apps.who.int/ebola/ebola-
ituation-reports), which is caused by the Makona variant of the
aire ebolavirus (EBOV) species. Its genome is a 19 kb long single-
tranded, negative-sense RNA. Rapid diagnosis is a critical infection
ontrol measure, particularly in light of EVD’s early symptoma-
ology, which is indistinguishable from that of other infections
ncluding malaria [1]. Ebola virus diagnostics have improved
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considerably following the development of real-time reverse tran-
scription PCR (real-time RT-PCR) assays capable of rapidly detecting
viral RNA in blood specimens [2–7]. Their ability to estimate viral
loads in blood, which correlate with clinical outcome [8–11], as well
as in various body ﬂuids [12–20], makes them useful tools in the
post-diagnostic phase. The recent implementation, though some-
what controversial, of a negative blood real-time RT-PCR result as
a discharge criterion has only increased these assays’ importance
[21,22].
Yet commercial molecular diagnostic assays were made avail-
able only in 2014. Validation results of real-time RT-PCR assays
recently used in the ﬁeld in West Africa and in other countries for
screening are limited and not publicly available, and no assays have
yet been compared systematically.
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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. Objectives
We  undertook the present comparative study to evaluate the
erformance of several commercial and in-house EBOV real-time
T-PCR assays in order to inform future selections and use of these
ools both in the ﬁeld and in high-resource settings.
. Study design
The study ﬂow chart is shown in Fig. 1.
.1. EBOV RNAs
C5 (GenBank no. KJ660348) and C15 RNAs (GenBank no.
J660346) extracted from Vero-cell cultures after inoculation
ith serum from patient C5 in Guéckédou and patient C15 in
issidougou [23] were kindly provided by the Swiss Institute
or NBC-Protection (Spiez Laboratory, Biology–Virology Group,
piez, Switzerland). Alignment of the two sequences revealed
 nucleotide changes (99% nucleotide sequence homology): two
ere located in the N gene at positions 2124 and 2185, one in
he GP gene at position 6909, and two in the L gene at positions
3,856 and 15,660. None of these positions are targeted by any of
he real-time RT-PCR assays tested in our study, except possibly for
he position 13,856 nucleotide change, which could be involved in
he target sequence of the RealStar® Filovirus Screen RT-PCR Kit
.0, the Roche LightMix® Modular Ebola Virus Zaire assay, and/or
he FTD® Ebola real-time RT-PCR.
In order to determine both the analytical sensitivity and the lin-
ar range of selected real-time RT-PCR assays, we  used two  RNA
ranscripts 990 bases long (TriLink BioTechnologies, San Diego,
SA) at known concentrations. One spans the L gene (nt 12,792 to
t 13,781 of the genomic strand, GenBank ref: KM233117) and the
ther the NP gene (nt 374 to nt 1363 of the genomic strand, GenBank
ef: KM233117); together these cover all real-time RT-PCR targets
sed in this study. We  also used RNA extracted from the serum of
n EVD patient managed in our institution [19]. All RNA in the same
xperiment, either extracted or transcribed in vitro, underwent the
ame freeze–thaw cycle.
.2. RNA extraction
RNA extraction was performed with the EasyMag automate
NucliSENS® EasyMAG, bioMérieux, Geneva, Switzerland) follow-
ng the manufacturer’s instructions. 400 l of specimen (Ebola Zaire
ositive serum) were inactivated by 1 ml  of lysis buffer (EasyMAG®
ysis Buffer), followed by nucleic acid extraction with a ﬁnal elution
olume of 50 l.
.3. rRT-PCR assays
The following six commercial assays were selected based on
heir availability on the market in Switzerland at the time of this
tudy and their ability to be conducted on open platforms and
dapted to the speciﬁcations of an average clinical microbiology
aboratory: RealStar® Filovirus Screen RT-PCR Kit 1.0 (ref: 441013,
ltona, Hamburg, Germany) and the Zaire Ebolavirus assay from
he RealStar® Filovirus Type RT-PCR Kit 1.0 (ref: 451003, Altona,
amburg, Germany), Roche LightMix® Modular Ebola Virus Zaire
ref: 40-0666-96, Roche, Rotkreuz, Switzerland), FTD® Ebola (ref:
TD-71-64, Fast-track Diagnostics (FTD), Sliema, Malta), Lifetech
bola Virus (Zaire 2014) and Lifetech Lyophilized Ebola Virus (Zaire
014) (ref: 4489990, Life Technologies, Waltham, USA). These tests
re referred to as Altona Screen, Altona Type, Roche, FTD, Lifetech
nd Lifetech L, respectively, throughout the manuscript.cal Virology 77 (2016) 9–14
According to the manufacturer’s instructions, the following real-
time PCR platforms were suitable for each commercial kit:
Altona screen:
Mx 3005PTM QPCR System (Stratagene), VERSANT® kPCR Molec-
ular System AD (Siemens), ABI Prism® 7500 SDS and 7500 Fast
SDS (Applied Biosystems), LightCycler® 480 Instrument II (Roche),
Rotor-Gene® 3000/6000 (Corbett Research), Rotor-Gene® Q5/6
plex Platform (QIAGEN), and CFX96TM/Dx Real-Time System (BIO-
RAD).
Altona type:
VERSANT® kPCR Molecular System AD (Siemens), ABI Prism®
7500 SDS and 7500 Fast SDS (Applied Biosystems), LightCycler® 480
Instrument II (Roche), Rotor-Gene® 3000/6000 (Corbett Research),
Rotor-Gene® Q5/6 plex Platform (QIAGEN), and CFX96TM/Dx Real-
Time System (BIORAD).
Roche:
LightCycler® 480 II Instrument (Roche), and Cobas z 480 (Roche).
FTD:
ABI Prism® 7500 SDS, 7500 Fast SDS, and ABI ViiA7
(Applied Biosystems), CFX96TM/Dx Real-Time System (BIORAD),
LightCycler® 480 II Instrument (Roche), Rotor-Gene® 3000/6000
(Corbett Research), and SmartCycler® (Cepheid).
Lifetech and Lifetech L:
7500 Fast SDS, ABI ViiA7, and QuantStudio real-time PCR sys-
tems (Applied Biosystems).
In addition, we  tested 5 in-house real-time RT-PCR assays: The
real-time RT-PCR designed by Gibb and colleagues in 2001 [2], as
well as a modiﬁed version, which we  adapted according to the
viral circulating sequences in 2014; a modiﬁed version of the Ebola
Zaire-TM assay designed in 2010 [7], which was adapted according
to 2014 EBOV sequences by the Swiss Institute for NBC-Protection
(Spiez Laboratory, Biology–Virology Group, Spiez, Switzerland);
and two  in-house real-time RT-PCR assays, which were designed
according to publicly available Ebola sequences through October
2014, the “EBOV-GP-GE-14” and the “EBOV-L-GE-14” real-time RT-
PCRs, targeting the GP and L genes respectively. These in-house
assays are referred to as EBOGP-1D, EBOGP-1D14, Ebola Zaire-TM,
EBOV-L-GE-14 and EBOV-GP-GE-14, respectively. Primers pairs
and probes were designed using Primer Express software version
3.0.
The Roche, Altona Screen and Altona Type assays were used with
the LightCycler 480 thermocycler (Roche Diagnostics, Rotkreuz,
Switzerland) while the FTD, Lifetech and Lifetech L assays were run
with the ViiA7 thermocycler (Life Technologies, Waltham, USA),
according to the manufacturer’s instructions. All non-commercial
real-time RT-PCRs were run using the StepOne Plus thermocycler
(Life Technologies Waltham, USA). Characteristics of the 11 eval-
uated real-time RT-PCR assays, including cycling conditions and
primers’ and probes’ sequences, when available, are summarized
in Table S1.
3.4. Lower limits of detection and quantiﬁcation, and EBOV RNA
quantiﬁcation
For each selected real-time RT-PCR assay, known concentrations
of in vitro transcribed RNAs (see above) were run in triplicate in two
separate experiments to establish standard curves and deﬁne the
limit of detection (LOD) and the lower limit of quantiﬁcation (LOQ).
The LOD was  deﬁned as the lowest RNA concentration detected in
all of the six replicates. The LOQ was  deﬁned based on both trip-
licate experiments as the lowest RNA concentration that could be
plotted on a standard curve with a slope between −3.1 and −3.6
(corresponding to a PCR efﬁciency between 90% and 110%), an r2
value above 0.95, and visually limited dispersion around the curve.
For EBOV RNA quantiﬁcation in the clinical specimen, a standard
P. Cherpillod et al. / Journal of Clinical Virology 77 (2016) 9–14 11
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. Results
.1. Analytical sensitivity comparison of six commercial and ﬁve
n-house rRT-PCR assays
Each of the six commercial and ﬁve in-house assays was
valuated by end-point dilution using 5-fold dilutions of two
ulture-derived full-length EBOV genome RNAs, related to isolates
ollected in Guinea in March 2014 (named C5 and C15 RNAs) (Fig. 1
nd Table S2).
While all 11 assays could detect RNA from both isolates, the
ommercial kits tended to be more sensitive. Since the in-house
eal-time RT-PCRs provided no advantages in terms of performance
r ease of use, they were not selected for further evaluation. We  did
ot retain the Lifetech Ebola Virus (Zaire 2014) assay for further
esting either, as it was less sensitive than its lyophilized counter-
art and lacked its practical advantages.
The LOD was determined for the ﬁve most promising assays
Altona Screen, Altona Type, Roche, FTD, and Lifetech L), using serial
ilutions of quantiﬁed in vitro transcribed RNAs (Fig. 2, Table 1). As
an be seen in Fig. 2, which represents two separate experiments
erformed seven months apart, the inter-assay variability is very
mall.ection; LOQ: lower limit of quantiﬁcation.
4.2. Lower limit of quantiﬁcation
The ﬁve selected assays were further tested for their quantiﬁca-
tion abilities (Fig. 2, Table 1). Of note, the highest RNA concentration
tested in our analysis was 6.25E9 RNA copies/ml, which did not
reach the upper limit of quantiﬁcation for any assay.
4.3. EBOV RNA quantiﬁcation and end-point dilution using serum
of an EVD patient
The ﬁve commercial real-time RT-PCRs were also run in dupli-
cate on 3-fold dilutions of RNA extracted from a serum sample
withdrawn from an EVD patient managed in our institution [19]
(Table 1). The EBOV RNA quantiﬁcation values obtained with the
various assays in the undiluted serum were as follows: 1.16E6 RNA
copies/ml (Altona Screen), 1.13E5 RNA copies/ml (Altona Type),
9.5E4 RNA copies/ml (Roche), 4.0E4 RNA copies/ml (FTD), and 2.5E4
RNA copies/ml (Lifetech L).
4.4. Ease of use and turnaround time
The complexity of technical manipulations was comparable
between the ﬁve assays, except for the Lifetech Lyophilized system,
which does not require any real-time RT-PCR mix  preparation. For
each assay, we  estimated separately the handling time from RNA
extraction to real-time RT-PCR and the real-time RT-PCR cycling
time, and the total turnaround time (Table 1).
12 P. Cherpillod et al. / Journal of Clinical Virology 77 (2016) 9–14
Fig. 2. Graphical representation of standard curve, linearity range, lower limit of quantiﬁcation (LOQ) and limit of detetction (LOD) for each EBOV rRT-PCR assay. Each plot
shows  values obtained from two separate experiments in which serial dilutions of in vitro transcribed EBOV RNA were run in triplicate. Red diamonds represent the ﬁrst
experiment and blue diamonds the second. The lowest RNA concentration for which the line passes through represents the LOQ. The vertical grey dashed line represents the
LOD.  For each assay, the cycling number recommended by each manufacturer is represented by the highest number indicated on the y axis. Diamonds situated above the
maximum cycle line represent RNA dilutions that were not detected. Slope and r2 values are indicated for each curve. (For interpretation of the references to color in this
ﬁgure  legend, the reader is referred to the web  version of this article.)
Table 1
Comparison of ﬁve selected EBOV rRT-PCR assays.
Assay LOD (in vitro
transcribed RNA
copies/ml)
LOQ (in vitro
transcribed RNA
copies/ml)
Highest patient
RNA dilution
detected
Handling time
from extraction
to rRT-PCRa
(min)
rRT-PCR cycling
time (min)
Total turnaround
time (min)
Storage temperature
Altona Screen 1250 12,500 27× 70–100 120 190–220 −20 ◦C
Altona  Type 6250 625,000 27× 70–100 120 190–220 −20 ◦C
Roche  1250 6250 27× 70–105 80 150–185 −20 ◦C
FTD  625 1250 81× 70–100 75 145–175 −20 ◦C
Lifetech  L 62.5 625 243× 55–80 50 105–130 2–8 ◦C
a Nucleic acid extraction, rRT-PCR mix  preparation, plate pipetting LOD: limit of detection; LOQ: lower limit of quantiﬁcation.
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. Discussion
We  provide the ﬁrst systematic comparison of several EBOV
eal-time RT-PCR assays, six of which are commercially available,
sing serial dilutions of full-length EBOV RNAs from the 2013–2015
VD outbreak. In-house assays did not match the performance of
he commercial kits even after primer adaptations in line with
ecently isolated EBOV sequences. This could be explained in part
y the lack of extensive reagent optimization.
The ﬁve most promising assays, all commercially available
Altona Screen, Altona Type, Roche, FTD, and Lifetech L), were
elected for further evaluation using quantiﬁed RNA transcripts.
The Lifetech Lyophilized assay displayed the best analytical sen-
itivity with an LOD of 62.5 RNA copies/ml, and the lowest LOQ (625
NA copies/ml), which may  be explained in part by the kit’s rela-
ively high RNA eluate volume. Indeed, 25 l of eluate is required;
his is 2.5 to 5 times more than that required by the Roche, FTD and
oth Altona assays.
Turnaround times ranged from two (Lifetech Lyophilized) to
.5 h (both Altona assays). The differences are relatively small,
owever, and should have little impact on patient management.
omplexity of use and reagent storage constraints are likely to be
ore signiﬁcant issues in the ﬁeld.
Altogether, despite differences in analytical sensitivities and
OQs, the Altona Screen, Roche, FTD, and Lifetech L assays all dis-
layed analytical sensitivities high enough to ensure accurate EVD
iagnosis and linear quantiﬁcation ranges sufﬁcient to assess viral
inetics, at least when dealing with high RNA concentrations.
The Zaire Ebolavirus assay from the RealStar® Filovirus Type RT-
CR Kit 1.0 was the least sensitive and the least suited for EBOV RNA
uantiﬁcation. This is a minor issue, however, if the assay is used
rimarily, as its name implies, to type the Zaire ebolavirus species.
Nevertheless, the different sensitivities exhibited by the real-
ime RT-PCR kits can have considerable clinical impact. For
nstance, as the viral RNA load decreases during the recovery phase,
he various real-time RT-PCR assays may  yield undetectable results
t different time points, potentially resulting in prolonging or short-
ning of patient isolation time. This issue was exempliﬁed during
he management of an EVD infected patient in our center, as we
btained different real-time RT-PCR results with the Roche and
ltona assays run on the same samples during the convalescent
hase [19]. However, one can argue that when a patient shows
igns of clinical cure, the low-level detection of viral RNA proba-
ly reﬂects genomic remnants rather than residual infectious virus
24]. Therefore, high Ct values obtained during the recovery phase
hould probably not be overemphasized.
EBOV RNA quantiﬁcation by real-time RT-PCR is clinically use-
ul, since high viremia is correlated with a higher mortality [8–11].
recise EBOV RNA quantiﬁcation will also be a valuable tool in trials
valuating antiviral agents.
It should be noted, however, that in this study we  did not
erform a complete real-time RT-PCR quantiﬁcation validation,
ut rather assessed their respective quantiﬁcation potential. A
horough validation according to the Minimum Information for
ublication of Quantitative Real-time PCR Experiments (MIQE)
uidelines [25] would be essential for any formal assessment of
BOV-RNA quantiﬁcation performance. Moreover, as shown with
he quantiﬁcation of EBOV RNA in the serum of an EVD patient, RNA
opies/ml values varied considerably according to the real-time RT-
CR assay, from 4.41 to 6.07 log10 RNA copies/ml. This variability
an have an impact on viral load quantiﬁcation results in clinical
nvestigations, and hence on the conclusions drawn by such stud-
es. Therefore, in order to compare quantiﬁcation values obtained
ith different tests, they should be expressed in international units
IU) per millilter using an international quantiﬁcation standard, as
as been done for other viruses.cal Virology 77 (2016) 9–14 13
The Lifetech L and FTD assays displayed remarkably low LOQs,
625 and 1250 RNA copies/ml, respectively, which could be interest-
ing in EBOV RNA quantiﬁcation in a research context. The Lifetech L
assay, which to the best of our knowledge did not have the opportu-
nity to be tested in the ﬁeld during the 2013–2015 EVD outbreak,
displays many interesting features. The absence of real-time RT-
PCR mix  preparation and freezer requirements, short turnaround
time, high sensitivity and low LOQ render this assay particularly
suitable in the context of an outbreak in limited-resource settings,
in which cold chain management can be challenging.
Our study has several limitations. The ﬁrst is the lack of sequence
data regarding the primers and probes included in commercial
assays, which is a consequence of the restrictive data-sharing
policies applied by various agencies. Second, our study is not
exhaustive, as we  made a selection of available assays at a given
time and at a speciﬁc place, and that were adapted to our labora-
tory. Third, it should be noted that we used a nucleic acid extraction
procedure (EasyMag) not typically used in West Africa, and three
different thermocyclers according to the different assays. Finally,
the present analysis is focused on the 2013–2015 EVD epidemic in
West Africa, and our conclusions are thus relevant to the Makona
EBOV variant currently circulating. Indeed, while the Altona Screen
and Roche assays performed well on RNA from the 2001 EBOV epi-
demic in Gabon, the same was not true for the FTD assay (data
not shown). This illustrates the need to adapt real-time RT-PCR
assays according to potential viral sequence evolution, as stressed
by Sozhamannan et al. [26].
In conclusion, among 11 EBOV real-time RT-PCR assays, com-
mercial kits were superior to in-house assays; among the former,
the Lifetech L assay displayed the highest sensitivity and ease of
use as well as the lowest turnaround time.
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